Searched for
BETA DRUGS EXPANSION
Ignore volatility and look for long-term opportunities: 5 mid-cap stocks from different sectors with upside potential of over 23%While the Nifty and Sensex are volatile, the number of stocks advancing and declining, indicative of market breadth, are pretty much even. ...- Largecap stocks and financial sectors offer the most value in short time: Sushant BhansaliSushant Bhansali, CEO of Ambit Asset Management, sees short-term value in largecap stocks and financials, but advises focusing on companies...
- For risk-takers with a long-term perspective: 1 small and 7 mid-cap stocks from different sectors with upside potential of up to 44%The market is once again witnessing some volatility and profit-booking. Don’t panic: We have witnessed pretty much similar conditions sever...
- Beta Drugs raises Rs 117 crore from HealthQuadBeta Drugs secured Rs 117 crore from HealthQuad and other investors to expand globally and boost operational capabilities. The oncology-foc...
- Volatility or opportunity, depends on stock & your ability: 5 mid-cap stocks from different sectors with an upside potential of up to 42%The market is volatile with a bearish bias, and the chances that it will remain so for some time are high. But then volatility is not new, ...
- Medtech startup SigTuple raises $4 million from Sidbi Venture Capital, othersThe startup, which specialises in digital microscopy solutions powered by AI and robotics, has raised $50 million to date. The new capital ...
- Forget additional 2.5% LTCG, finally it is economy and earnings: 4 midcap stocks from different sectors with an upside potential of up to 37%The reaction of the street to the increase in both short and long capital gains tax is stronger because it was not expected by any section ...
- Focus on capital protection in volatile times: 4 midcap stocks with potential upside of up to 39%In equity markets, whatever precaution one might take, the probability of a mistake of getting stuck with a wrong stock cannot be ruled out...
- With more checks and balances for better risk management: 4 midcap stocks with potential upside of up to 25%After a relentless rally for the last ten months, the mid-caps segment of the market is witnessing some profit booking/ correction/ rationa...
- Is the worst behind them? 5 agrochemical stocks with upside potential of up to 38%Majority of businesses have a cycle of ups and downs. The question is whether the downs are cyclical in nature or they have come up due to ...
- Is the worst of headwinds behind them? 5 agrochemical stocks with upside potential of up to 32%While they had been listed for a long period of time, Indian companies in agro chemical space got the real attention of the street only fou...
- In the short term, IT and banking to benefit most as FIIs return: Rajat Sharma“High beta stocks – IT and banking – tend to do really well when there is a lot of foreign money coming in and they suffer the most when th...
- Drug used to reduce blood fats may cut SARS-CoV-2 infection by 70 per cent: StudyThe team led by researchers from the University of Birmingham in the UK found that fenofibrate and its active form fenofibric acid can sign...
- Stocks in the news: Infosys, Allahabad Bank, DHFL, SBI, Jet and Sun PharmaMorgan Stanley has double upgraded Sun Pharma stock, ET Now reported.
- Select low-beta stocks may be better bets in this marketFive stocks to look at in the current market scenario marked by uncertainties.
- Global brokerages positive on banking, pharma sectors; five stocks to bet onIn the past week, the beta rally lost steam. Here are the top four recommendations from various brokerage firms for a minimum investment pe...
- Market will be happy if RBI hikes repo rate and cuts MSF rate: Nilesh Shah, Axis DirectEven if Raghuram Rajan hikes the repo rate and lowers the MSF rate, the market will be more than happy, says Nilesh Shah.
- Markets want Narendra Modi as the next PM: Manish Sonthalia, VP & Fund Manager, Motilal Oswal Asset Management'Valuations are beaten down for the bulk of the market, but visibility is not there and where the visibility is you get stocks at reasonabl...
- Markets willing to pay premium for good earnings growth: Jitendra Sriram, HSBC Securities"Yesterday’s selling was a bit of a surprise. A lot of it has to do with the amount of arbitrage money sloshing around in the Indian system...
- Rel Life Sciences to focus on R&D, for nowThe company is all set to launch fifth biosimilar drug and seeks approvals for clinical trials and stem-cell treatment.
Load More
